Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001923 · ClinicalTrials.gov registry record · Phase 1

Transcranial Magnetic Stimulation for the Treatment of Phantom Pain

A Phase 1 study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT00001923 is a Phase 1 study that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001923, a Phase 1 study, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

Phantom pain refers to the sensation of pain felt by patients who have had a limb amputated. The treatment of phantom pain is often disappointing and is unable to provide adequate relief to the patients. The area of the brain involved (posterior parietal cortex \[PPC\]) is found on the opposite side of the amputated limb. For example, if a patient has the right arm amputated, the left posterior parietal cortex is involved in the phantom pain. Researchers believe that if they can decrease activity in the posterior parietal cortex they may be able to reduce phantom pain. Researchers plan to use low frequency (1 Hz) transcranial magnetic stimulation (TMS) to decrease the excitability of the PPC opposite the side of the amputated limb. TMS involves the placement of a cooled electromagnet with a figure-eight coil on the patient's scalp and turning on the magnetic flux. This permits non-invasive, relatively localized stimulation of the surface of the brain (cerebral cortex). When an area of the brain is stimulated a period follows when that area cannot be stimulated again. In this case, researchers plan to use TMS to stimulate the PPC in order to decrease the level of excitability there.

Interventions

  • PROCEDURE Transcranial magnetic stimulation

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 1998-12
Est. Completion 2002-12
Phase Phase 1

What the Registry Record Tells You About NCT00001923

The ClinicalTrials.gov registry entry for NCT00001923 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Transcranial magnetic stimulation is the first listed.

NCT00001923 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00001923 about?

NCT00001923 is a clinical study titled "Transcranial Magnetic Stimulation for the Treatment of Phantom Pain". Phantom pain refers to the sensation of pain felt by patients who have had a limb amputated. The treatment of phantom pain is often disappointing and is unable to provide adequate relief to the patients. The area of the brain involved (posterior parietal cortex \[PPC\]) is found on the opposite side...

What is the current status of trial NCT00001923?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 1998-12. Estimated completion is 2002-12.

What interventions are being tested in trial NCT00001923?

The interventions under investigation include: Transcranial magnetic stimulation (PROCEDURE).

Who is sponsoring clinical trial NCT00001923?

This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.